Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antonio Vargiu is active.

Publication


Featured researches published by Antonio Vargiu.


Drug Safety | 2008

Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Domenico Motola; Antonio Vargiu; Roberto Leone; Anita Conforti; Ugo Moretti; Alberto Vaccheri; Giampaolo Velo; Nicola Montanaro

AbstractBackground: The reporting of adverse drug reactions (ADRs) is the mainstay of post-marketing surveillance systems. Under-reporting and selective reporting are considered the main limitations of a spontaneous reporting-based pharmacovigilance system. However, excessive reporting induced by external events may also impair signal detection by increasing the noise level. Objective: The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors (‘statins’) and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors (‘coxibs’) and increase in cardiovascular risk. Methods: The study was based on data from spontaneous reporting in six Italian regions collected from January 1995 to December 2005. We analysed a 10-year period as a reasonable time interval around the four situations of interest, highlighting the influence of regulatory measures on the rate of ADR reporting (number of reports per million inhabitants). Chi-squared tests were used to assess the statistical significance of any changes in ADR reporting. Drug sales data were also studied to examine possible changes in drug use. Sales data were expressed as daily defined dose per 1000 inhabitants per day. Results: ACE inhibitors: a 5-fold increase in the reporting rate of ACE inhibitor-induced cough was observed in 1998 and 1999 following a restriction on reimbursement for angiotensin receptor blockers introduced in 1998 and removed at the end of 1999. Statins: after the withdrawal of cerivastatin in 2001, the ADR reporting rate increased more than 4-fold, with musculoskeletal ADRs representing about 60% of all the ADRs reported in that year, and progressively decreased in the following years. Nimesulide: an increase in hepatic ADR reporting was observed after withdrawal of the drug from the Finnish and Spanish markets in 2002. Coxibs: no important changes in the rate of cardiovascular events reporting in the period 2000–4 were observed. In 2005, after the withdrawal of rofecoxib in September 2004, both the ADR reporting rate and sales of the drug decreased drastically. Conclusion: Our data suggest that spontaneous ADR reporting can be influenced in different ways by external events. Our data emphasize the need for educational initiatives aimed at increasing the doctor’s and patient’s awareness of the usefulness and the limitations of spontaneous reporting in the pharmacovigilance system. Such initiatives should use appropriate risk communication strategies in order to avoid unnecessary alarm, which could cause unjustified interruption of therapies or misplaced confidence in new drugs.


Journal of Antimicrobial Chemotherapy | 2008

A 3 year survey on the use of antibacterial agents in five Italian hospitals

Alberto Vaccheri; Maria Chiara Silvani; Laura Bersaglia; Domenico Motola; Petar Strahinja; Antonio Vargiu; Elisabetta Poluzzi; Nicola Montanaro

BACKGROUND Misuse of antimicrobial agents in hospitals may cause the emergence of resistant microorganisms, as well as increased costs and unnecessary exposure of patients to drugs. We investigated the pattern of antibiotic consumption in 2002-04 in a sample of Italian hospitals, and compared this with antibiotic consumption data in primary healthcare in the Emilia-Romagna region. METHODS The study was carried out in five hospitals of the Emilia-Romagna region and 2002-04 drug use data were obtained from the pharmacy services. Data were analysed by clinical areas and single wards and were expressed by ATC classification and defined daily doses (DDD)/100 bed days. Prescription data of antibacterials in primary care in the same period were also analysed. RESULTS Antibiotic consumption increased by 18% in the 3 year period. Combinations of penicillins and beta-lactamase inhibitors were the most used drugs, followed by fluoroquinolones and third-generation cephalosporins. Penicillins plus beta-lactamase inhibitors increased in all the clinical areas by over 40%, and fluoroquinolones sharply increased in medical units (+29%). Third-generation cephalosporins remained fairly stable in paediatrics and surgery, but increased in medicine (+18%). Glycopeptides accounted for 4.3% of total antibiotic consumption with a peak of 10% in intensive care units. Antibacterial prescription in primary care showed a pattern similar to that of hospitals. CONCLUSIONS We found a considerable increase in antibiotic use over time and a marked preference for wide-spectrum antibiotics such as penicillins plus beta-lactamase inhibitors, fluoroquinolones and third-generation cephalosporins; thus raising concern about appropriate use. These results could represent the basis for educational initiatives aimed at rationalizing the use of antibiotics in hospitals.


European Journal of Clinical Pharmacology | 2005

Initial treatment of hypertension and adherence to therapy in general practice in Italy

Elisabetta Poluzzi; Petar Strahinja; Antonio Vargiu; Giacomo Chiabrando; Maria Chiara Silvani; Domenico Motola; Giulia Sangiorgi Cellini; Alberto Vaccheri; Fabrizio De Ponti; Nicola Montanaro


European Journal of Clinical Pharmacology | 2008

Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy.

Elisabetta Poluzzi; Petar Strahinja; Monica Lanzoni; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Antonio Gaddi; Alberto Vaccheri; Nicola Montanaro


British Journal of Clinical Pharmacology | 2007

Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage

Elisabetta Poluzzi; Petar Strahinja; Alberto Vaccheri; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Giulio Marchesini; Fabrizio De Ponti; Nicola Montanaro


European Journal of Clinical Pharmacology | 2006

Hepatic adverse drug reactions: a case/non-case study in Italy

Domenico Motola; Antonio Vargiu; Roberto Leone; Alfredo Cocci; Francesco Salvo; Barbara Ros; I. Meneghelli; Mauro Venegoni; Paola Cutroneo; Alberto Vaccheri; Gianpaolo Velo; Nicola Montanaro


Current Drug Safety | 2012

Ticlopidine Safety Profile: A Case/Non-Case Study on the Basis of the Spontaneous ADRs Reporting in Italy

Domenico Motola; Chiara Biagi; Roberto Leone; Mauro Venegoni; Francesco Lapi; Paola Cutroneo; Antonio Vargiu; Roberto Bonaiuti; Nicola Montanaro; Alberto Vaccheri


Drug Safety | 2007

The Influence of Notoriety Bias on ADR Spontaneous Reporting Rate

Giampaolo Velo; Domenico Motola; Antonio Vargiu; Lara Magro; I. Meneghelli; Alberto Vaccheri; Anita Conforti; Nicola Montanaro


Basic & Clinical Pharmacology & Toxicology | 2007

Changes in prevalence and pattern of drug use in a ten years period in Italy. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics

Maria Chiara Silvani; Domenico Motola; Elisabetta Poluzzi; Petar Strahinja; Antonio Vargiu; Chiara Biagi; Alberto Vaccheri; Nicola Montanaro


Pharmacoepidemiology and Drug Safety | 2006

Antibiotic use in Italian hospitals 2002-2004.

Maria Chiara Silvani; Elisabetta Poluzzi; Domenico Motola; Petar Strahinja; Antonio Vargiu; Laura Bersaglia; Alberto Vaccheri; Nicola Montanaro

Collaboration


Dive into the Antonio Vargiu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge